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Abstract
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The
ultimate goal of anti-HBV treatment is to prevent the development of
hepatocellular carcinoma (HCC). During the last two decades, with the use of
currently available anti-HBV therapies (lamivudine, entecavir and tenofovir
disoproxil fumatate), there has been a decrease in the incidence of HBV-
associated HCC (HBV-HCC). Furthermore, several studies have demonstrated a
reduction in recurrent or new HCC development after initial HCC tumor
ablation. However, during an observation period spanning 10 to 20 years, several
case reports have demonstrated the development of new, subsequent new and
recurrent HCC even in patients with undetectable serum HBV DNA. The
persistent risk for HCC is attributed to the presence of covalently closed circular
DNA (cccDNA) in the hepatocyte nucleus which continues to work as a template
for HBV replication. While a functional cure (loss of hepatitis B surface antigen
and undetectable viral DNA) can be attained with nucleos(t)ide analogues, these
therapies do not eliminate cccDNA. Of utmost importance is successful
eradication of the transcriptionally active HBV cccDNA from hepatocyte nuclei
which would be considered a complete cure. The unpredictable nature of HCC
development in patients with chronic HBV infection shows the need for a
complete cure. Continued support and encouragement for research efforts aimed
at developing curative therapies is imperative. The aims of this minireview are to
highlight these observations and emphasize the need for a cure for HBV.
Key words: Hepatitis B; Hepatocellular carcinoma; Antiviral therapy; Persistent Risk for
hepatocellular carcinoma; Tumor ablation
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Core tip: Despite the advances in the management of hepatitis B virus (HBV) infection
and HBV-associated hepatocellular carcinoma (HCC), the risk for new, subsequent new
and recurrent HCC persists even after over a decade of antiviral therapy and initial tumor
ablation. This is due to the inability of the current antiviral therapy to eliminate the
covalently closed circular DNA from the hepatocyte nucleus. There is a great need for an
HBV cure drug.
Citation: Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann
HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite
successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus
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URL: https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm
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INTRODUCTION
Since the discovery of hepatitis B virus (HBV) by Blumberg et al[1] in 1965 and the
development of the first HBV vaccine in 1983, much knowledge has been obtained
regarding the  pathogenesis,  hepatocarcinogenesis,  epidemiology and molecular
biology of HBV as well as the antiviral treatment.
With vaccination,  there  has  been a  decrease in  the number of  infected people
globally especially in the younger generations.  There has also been a significant
increase in survival of HBV infected individuals due to antiviral treatment and earlier
detection of hepatocellular carcinoma (HCC) with simultaneous antiviral treatment.
However HBV is still responsible for 786000 deaths in 2010 with 341000 from HCC
and 312000 attributed to cirrhosis[2].
HBV is a major public health issue with more than 257 million carriers living today,
and up to one million who die annually from HBV-related liver disease including
HCC[3,4]. HCC is the sixth most common cancer and the third leading cause of cancer
deaths worldwide. Chronic infection with HBV is responsible for 50% of HCC cases
worldwide[5,6]. Current therapies available to treat chronic hepatitis B (CHB) include
interferon and the nucleos(t)ide analogues (NAs): Lamivudine, adefovir, entecavir,
telbivudine, tenofovir disoproxil fumarate and the recently FDA-approved tenofovir
alafenamide. Several studies have been conducted in the past to assess the impact of
antiviral  therapies,  specifically  lamivudine,  entecavir  and tenofovir,  on  disease
progression and HCC development[7-10]. Multiple studies have demonstrated that for
patients diagnosed with HBV-related HCC, improved survival can be attained with
adjuvant antiviral  therapy following curative liver resection and/or local  tumor
ablation[11,12].
Current antiviral therapies used to treat CHB control viral replication through
inhibition  of  reverse  transcriptase  and  subsequent  interruption  of  HBV  DNA
formation. While treatment can slow and/or prevent the progression of liver disease,
it does not eliminate the covalently closed circular DNA (cccDNA) from infected
hepatocytes and is therefore unable to cure the infection. As a result, patients usually
require  lifelong  therapy  to  control  viral  replication  and  help  prevent
hepatocarcinogenesis.
However, it has been reported that despite several years of antiviral therapy, a
persistent risk for carcinogenesis still exists[13-15]. Studies have also demonstrated that
even after more than a decade of successful HBV suppression, the risk for HBV-
related HCC remains[16-18].  The aims of this minireview are to bring light to these
observations and emphasize the need for a cure for HBV[19-21].
HBV REPLICATION CYCLE AND HEPATOCARCINOGENESIS
HBV related hepatocarcinogenesis has been extensively described in the past[22-27].
HBV is an enveloped partially double-stranded relaxed circular DNA virus of the
Hepadnaviridae family. The viral replication cycle begins when HBV recognizes highly-
sulfated heparin sulfate proteoglycans on the hepatocyte surface and gains entry by
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binding the liver-specific receptor, sodium taurocholate co-transporting polypeptide
(NTCP or SLC10A1)[28,29].  Once in the cell, the virus enters the hepatocyte nucleus
where the relaxed circular DNA is converted to cccDNA. While little is known about
the formation and regulation of cccDNA, it is thought that most of the steps needed
for this conversion are provided by the host cell[19-21,30]. Viral cccDNA remains in the
nucleus of the infected host cell and is used as the template for transcription of four
viral  mRNA  intermediates.  These  mRNA  intermediates  eventually  undergo
translation to produce seven viral proteins including DNA polymerase and the core
protein. One of these mRNA intermediates, called pregenomic RNA, is critical for the
viral replication. It undergoes reverse transcription and serves as the template for new
viral DNA. The newly formed viral DNA and viral proteins form viral nucleocapsids
that obtain HBV envelope proteins prior to being released from the hepatocyte as
mature enveloped virions[19-21,30]. These virions then go on to infect other hepatocytes.
As to HBV associated hepatocarcinogenesis, inside the hepatocyte nucleus, HBV
DNA  integration  with  the  host  genome  takes  place  during  the  acute  phase  of
infection[31,32]. This integration is thought to be one of several mechanisms that leads to
carcinogenesis and HCC. Activation of cellular oncogenes,  inactivation of tumor
suppressor genes, chronic liver injury, inflammation and regeneration, activation of
cellular proto-oncogenes, suppression of growth regulating genes and increased HBx
protein have all been implicated in the development of HCC[33] (Figure 1).
CURRENT ANTIVIRAL THERAPIES FOR CHRONIC HBV AND
THE IMPACT ON HCC INCIDENCE
Current therapies available to treat CHB include interferon and NAs: lamivudine,
adefovir, entecavir, telbivudine, tenofovir disoproxil fumarate and the recently FDA-
approved  tenofovir  alafenamide.  While  interferon  works  through  immune
modulation and has a weak antiviral effect, the NAs inhibit viral replication through
direct inhibition of viral reverse transcriptase. The goal of these antiviral medications
is to improve quality of life and survival by preventing the progression of CHB and
development of cirrhosis and HCC. Currently the treatment objectives are categorized
as shown in Table 1. While a “functional cure” is defined as the loss of hepatitis B
surface antigen (HbsAg) and/or seroconversion to antibody to hepatitis B surface
antigen with undetectable serum HBV DNA, it is important to remember that this is
not a complete cure[19]. This complete cure is what is desperately needed to end the
persistent risk for HCC.
Decreased incidence of HCC with antiviral therapy
While a complete cure is not yet available, several studies have assessed the impact of
NAs on disease progression and HCC development. A randomized controlled trial by
Liaw et al[7] randomized patients with advanced fibrosis or cirrhosis secondary to CHB
to receive daily Lamivudine or placebo for up to 5 years. HCC occurred in 17/436
(3.9%)  of  patients  treated  with  Lamivudine  and  16/215  (7.4%)  of  patients  who
received placebo (P  =  0.047).  After  a  median treatment  duration of  32.4  mo,  the
incidence of HCC was significantly reduced in the Lamivudine group and the study
was stopped[7].
A retrospective study by Eun et al[8] conducted from March 1997 to February 2005
also showed a decreased incidence of HCC with use of lamivudine in patients with
chronic HBV and compensated cirrhosis. HCC occurred in 4.9% of patients in the
group treated with Lamivudine with sustained viral suppression compared to 25% of
patients in the untreated group.
Similar results have also been shown with newer antivirals such as entecavir and
tenofovir. Hosaka et al[9] assessed the risk of HCC in patients with CHB treated with
entecavir compared to a control group of treatment-naïve patients. After 5 years of
treatment, patients treated with entecavir had a cumulative HCC incidence of 3.7%
compared to 13.7% in the treatment-naïve group (P < 0.001). Similarly, Kim et al[10]
examined the incidence of HCC in patients treated with tenofovir disoproxil fumerate
(TDF). Patients with CHB, including those with cirrhosis, were treated with TDF and
assessed for incidence of HCC. The investigators found that there was a decreased
incidence of HCC noted by the third year of treatment with TDF compared to the
predicted incidence.
Improved survival with antiviral therapy after the development of HCC
Since the first antiviral drug for HBV became available, antiviral therapy has been
used in  patients  following surgical  resection or  local  ablative  therapy for  HBV-
associated HCC. Longer survival with concomitant antiviral therapy following tumor
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Figure 1
Figure 1  Hepatitis B replication life cycle.
ablation has been observed in a number of studies conducted in Japan, Hong Kong,
Taiwan and China since 2007. Similar observations of improved survival were first
reported in the United States in 2011[34]. A meta-analysis conducted by Yuan et al[11]
reviewed sixteen of these studies in an effort to investigate the effect of antiviral
therapy after curative therapy in patients with HBV-associated HCC. The papers in
the analysis included four studies from China,  three from Hong Kong, one from
Taiwan, six from Japan and one from the United States. The meta-analysis looked at
the impact of NAs on the one and three year recurrence rates, as well as one, three
and five year overall survival and disease-free survival rates. The results revealed that
NAs significantly reduced the recurrence of HBV-related HCC after curative therapy
and improved both overall survival and disease-free survival[11].
Liu et al[12] also conducted a meta-analysis to assess the effect of adjuvant antiviral
therapy following hepatectomy and/or percutaneous ablation for HBV-related HCC.
They looked at twenty-one studies that compared antiviral therapy with placebo or no
treatment. The primary end-points assessed were recurrence-free survival and overall
survival. While this meta-analysis did have some limitations including significant
between-study heterogeneity and most of the studies being observational in nature,
NAs did show a significant improvement in prognosis after curative treatment in
patients with HBV-associated HCC[12].
Development of new HCC while on successful antiviral therapy
While overall incidence of HCC has reduced with antiviral therapy, HCC can still
develop  despite  successful  viral  suppression,  most  commonly  in  patients  with
cirrhosis.  The most commonly reported cases of HBV-associated HCC developed
within five to ten years despite antiviral therapy[13-15]. However, recent observations at
the Liver Disease Prevention Center, Division of Gastroenterology and Hepatology of
Thomas Jefferson University Hospital  have demonstrated development of  HBV-
associated HCC even after a decade of successful viral suppression[16,17]. Patients from
these observations were maintained on antiviral treatment anywhere from 5.2-18.4
years  with  undetectable  serum  HBV  DNA  for  up  to  12.4  years  before  HCC
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Table 1  Definition of hepatitis B virus cure[19]
HBsAg Anti-HBs Viremia cccDNA
Functional cure - + - +
Complete cure - + - -
HbsAg: Hepatitis B surface antigen; Anti-HBs: Antibody to hepatitis B surface antigen; cccDNA: Covalently
closed circular DNA.
development.  Due to  close  monitoring and follow up,  most  of  the  tumors  were
discovered early and were ablated successfully (Table 2)[17].
Development of the subsequent new and recurrent HCC
After resection or ablation of the initial HCC, the patients were continued on antiviral
therapy and maintained successful viral suppression. However, the persistent risk for
subsequent new and recurrent HCC in this patient population has been observed. We
recently described three cases of subsequent new and recurrent HCC in patients who
underwent successful initial tumor ablation and had suppression of serum HBV DNA
for years. Figure 2 depicts these three patients and shows the time from their HBV
diagnosis  to  the  initial  HCC and eventual  development  of  subsequent  new and
recurrent HCC. One of these patients described in Figure 3 was diagnosed as HbsAg
(+) in 1987. She did not receive antiviral therapy as it was not available until after
1998. In 2000, thirteen years later, she was diagnosed with HCC. Following successful
transarterial  chemoembolization  (TACE)  and  radiofrequency  ablation  she  was
maintained on antiviral therapy for five years at which point she was found to have a
1.1  cm  ×  0.8  cm  arterially  enhancing  lesion  with  washout  appearance  near  the
previously treatment site on abdominal magnetic resonance imaging consistent with
recurrent HCC. She underwent TACE and was maintained on antiviral therapy for
another ten years at which point she developed another 0.8 cm recurrent HCC despite
an undetectable serum HBV DNA[18].
Need for HBV Cure
Without eradication of cccDNA from infected hepatocytes, HBV continues to carry the
risk of development of HCC despite functional cure being achieved as described
above. As we become more aware of the persistent risk for new, subsequent new and
recurrent HCC, we become more aware of our need for a cure for HBV infection.
Antiviral therapy is able to control viral replication and slow the progression of liver
disease  in  the  majority  of  treated  patients,  but  the  persistence  of  cccDNA  and
continual suppression of the innate and adaptive host immune response causes a
persistent risk of hepatocarcinogenesis. Several steps in the HBV replication cycle
have been identified as potential targets for future therapies. These therapies can be
separated into four categories based on their target of action: (1) complete inhibition
of HBV replication; (2) restoration of host innate immunity and adaptive anti-HBV T
and  B  cell  responses;  (3)  selective  sensitization  of  HBV infected  hepatocytes  to
immune elimination; and (4) direct targeting of cccDNA[21].
Complete inhibition of HBV replication: The first category, complete inhibition of
HBV replication, should have in theory already been achieved with existing NAs.
However, complete inhibition of HBV replication is not achieved with NAs alone
since inhibition of DNA polymerase is only one step of the entire HBV replication
cycle. If this had been achieved, we would see elimination of HBV DNA and even
cccDNA as infected hepatocytes are replaced. In addition to direct inhibition of HBV
DNA polymerase,  other  steps  in  the  replication  cycle  are  being  targeted.  Entry
inhibitors are being investigated and work through targeting the NTCP receptor
preventing de novo infection of hepatocytes as well as the spread of the virus from
infected hepatocytes to non-infected hepatocytes. Capsid inhibitors are also being
investigated and have the potential to work at several different steps in the HBV
replication cycle where the capsid is essential including genome packaging, reverse
transcription, intracellular trafficking and re-importation into the nucleus. These
therapies have the potential  to augment the action of  NAs and lead to complete
inhibition of HBV DNA[19].
Restoration of host innate and adaptive immunity: In regards to restoration of host
innate  and  adaptive  immune  responses,  several  targets  have  been  identified.
However,  the  challenge  of  stimulating  an  antiviral  immune-mediated  response
without  triggering detrimental  anti-HBV flares  is  difficult.  Inhibiting HBV gene
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Table 2  Development of hepatocellular carcinoma in patients with cirrhosis on long-term antiviral therapy[17]
Patient Date startTx
Chang in
child class
on Tx
Date HCC
Dx
Years on
anti-HBV
Tx at HCC
DX
Years with
HBV DNA
(-)
Age (yr) at
HCC Dx
Size (cm)
and site of
HCC
HBV DNA
at HCC Dx
Anti-HBV
Tx Status
1 4/1998 B→A 7/2007 9.3 3.41 53 1.1 Junction UD LAM + TDF Alive
2 6/2002 A→A 8/2007 5.2 4.7 70 1.0 Rt UD LAM + TDF Alive
3 1/1998 B→A 3/2008 10.2 8.2 68 2.8 × 2.5 UD LAM + TDF Dead
4 5/1998 A→A 2/2008 9.8 6.7 76 1.8 × 0.9 Lt UD LAM + TDF Alive
5 7/2004 B→B 9/2009 5.2 4.7 52 3.9 Rt UD LAM + TDF Alive
6 7/2001 B→B 9/2010 9.2 4.1 54 2.8 Rt UD LAM + TDF Dead
7 2/2004 A→A 6/2013 9. 3 7.7 57 2.5 Lt med UD TDF Dead
8 2/1996 A→A 7/2013 17.4 9.7 73 1.6 × 1.4 Rt UD TDF Dead
9 8/1997 A→A 6/2014 16.8 5.9 54 2.2 × 1.9 Lt
lat
UD ETV Alive
10 5/1996 A→A 10/2014 18.4 10.4 74 3.4 Rt UD LAM + TDF Dead
11 2/2000 A→A 4/2015 15.2 12.4 62 3.4 × 3.4 Rt UD TDF Alive
12 2/2000 B→A 5/2015 15.3 12.2 65 3.8 Rt UD TDF Alive
1Patient has been hepatitis B virus (HBV) DNA (-) until 3 years before HBV DNA became detectable (22 IU/mL) when tenofovir disoproxil fumarate was
added. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate. UD: Undetectable.
expression has been investigated with RNA interference and nucleic acid polymers.
Checkpoint inhibitors such as anti-PD-1 monoclonal antibodies currently used in
oncology are also being investigated. In HBV, the HBV-specific CD8+ T cells express
high levels of inhibitory molecules so inhibition of these checkpoint molecules can
rescue HBV-specific CD8+ T cells. Engineering HBV-specific T cells through transfer
of HBV-specific T cell receptors and therapeutic vaccines aimed at stimulating HBV-
specific T cell immunity in patients chronically infected with HBV are also under
investigation. Finally, toll-like receptor agonists are being developed to help recognize
the  virus  and  subsequently  stimulate  production  of  interferon-alpha  and  other
cytokines in an effort to activate natural killer cells and other lymphocytes[21].
Immune elimination of HBV infected hepatocytes: The third category of therapies
under investigation includes medications that target cellular inhibitor of apoptosis
proteins (cIAPs). These proteins have been found to attenuate TNF signaling during
HBV infection which leads to restricted death of infected hepatocytes. This lack of
infected hepatocyte death leads to viral persistence. Birinapant, a specific therapy
currently being investigated in preclinical models, antagonizes cIAP and has shown
anti-HBV activity[21].
Direct Targeting of cccDNA: The final category of potentially curative HBV therapies
under investigation involves direct targeting of cccDNA. There are several strategies
to target  cccDNA which include inhibition of  cccDNA formation,  destruction of
cccDNA and functional silencing of cccDNA through targeting proteins involved in
cccDNA transcription and/or stability.  Given the knowledge we have regarding
persistent cccDNA and impaired immune responses in patients with CHB, it is likely
that a combination of these newly investigated therapies will need to be used in order
to achieve complete cure[21].
CONCLUSION
The ultimate goal of HBV treatment is to prevent the development of HCC and death
from the virus. Of utmost importance is successful eradication of the transcriptionally
active HBV cccDNA from hepatocyte nuclei. While we currently aim for a functional
cure with loss of HBsAg and undetectable viral DNA, a complete cure can only be
attained  with  eradication  of  cccDNA.  The  several  concerns  regarding  the
unpredictable nature of HCC development in patients with CHB shows the need for a
cure and we should continue to support and encourage research efforts aimed at
developing curative therapies.
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Figure 2
Figure 2  Hepatocellular carcinoma in three patients with chronic hepatitis B[18]. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.
Figure 3
Figure 3  Persistent risk for recurrent hepatocellular carcinoma in a patient with chronic hepatitis B[18]. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus;
MRI: Magnetic resonance imaging; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation.
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